List of Dexilant Solutab drug patents
Dexilant Solutab is owned by Takeda Pharms Usa.
Dexilant Solutab contains Dexlansoprazole.
Dexilant Solutab has a total of 11 drug patents out of which 1 drug patent has expired.
Expired drug patents of Dexilant Solutab are:
- US6664276
Dexilant Solutab was authorised for market use on 26 January, 2016.
Dexilant Solutab is available in tablet, orally disintegrating, delayed release;oral dosage forms.
Dexilant Solutab can be used as treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; maintain healing of erosive esophagitis (ee) for up to 6 months.
The generics of Dexilant Solutab are possible to be released after 10 March, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6664276 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jan, 2023
(a day ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6664276
(Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jul, 2023
(5 months from now) | |
| US8784885 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(8 months from now) | |
|
US8784885
(Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(1 year, 2 months from now) | |
| US9238029 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(2 years from now) | |
| US8461187 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(2 years from now) | |
| US9011926 | TAKEDA PHARMS USA | Method for producing granules |
Feb, 2026
(3 years from now) | |
|
US8461187
(Pediatric) | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jul, 2026
(3 years from now) | |
| US8871273 | TAKEDA PHARMS USA | Method for producing granules |
Jan, 2028
(4 years from now) | |
|
US8871273
(Pediatric) | TAKEDA PHARMS USA | Method for producing granules |
Jul, 2028
(5 years from now) | |
| US9241910 | TAKEDA PHARMS USA | Orally-disintegrating solid preparation |
Mar, 2029
(6 years from now) | |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 26 January, 2016
Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; Maintain healing of erosive esophagitis (ee) for up to 6 months
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic